Hypertensive Crisis in the Setting of Non-Compliance by Barefield, Kimberly L & Lancaster, Scott
Philadelphia College of Osteopathic Medicine
DigitalCommons@PCOM
PCOM Scholarly Papers
2015
Hypertensive Crisis in the Setting of Non-
Compliance
Kimberly L. Barefield
Philadelphia College of Osteopathic Medicine, kimberlba@pcom.edu
Scott Lancaster
Follow this and additional works at: https://digitalcommons.pcom.edu/scholarly_papers
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by DigitalCommons@PCOM. It has been accepted for inclusion in PCOM Scholarly Papers by
an authorized administrator of DigitalCommons@PCOM. For more information, please contact library@pcom.edu.
Recommended Citation
Barefield, Kimberly L. and Lancaster, Scott, "Hypertensive Crisis in the Setting of Non-Compliance" (2015). PCOM Scholarly Papers.
1912.
https://digitalcommons.pcom.edu/scholarly_papers/1912
Central Annals of Clinical and Experimental Hypertension
Cite this article: Tackett KL, Lancaster S (2015) Hypertensive Crisis in the Setting of Non-Compliance. Ann Clin Exp Hypertension 3(2): 1021.
*Corresponding author
Kimberly L. Tackett, South University School of 
Pharmacy, 709 Mall Boulevard, Savannah, Georgia 
31406, USA, Tel: 912-201-8144; Fax: 912-201-8153; 
Email:  
Submitted: 09 January 2015
Accepted: 20 February 2015
Published: 23 February 2015
Copyright
© 2015 Tackett et al. 
 OPEN ACCESS 
Case Report
Hypertensive Crisis in the 
Setting of  Non-Compliance
Kimberly L. Tackett* and Scott Lancaster
Department of Pharmacy, South University School of Pharmacy, USA
INTRODUCTIONHypertension is a common chronic condition that affects approximately 78,000,000 adults within the United States [1]. 
Hypertensive crisis is defined as severe hypertension with a blood 
pressure of greater than 180/120 mmHg, and may be further 
classified as urgency or emergency [2,3]. Hypertensive urgency occurs in the setting of days to weeks and patients present most commonly with a headache.  Hypertensive emergency occurs in hours to days and the patient presents with evidence of end organ failure and severe headache.  Signs and symptoms of end 
organ failure are listed in (Table 1).  An estimated 7% of patients 
progress to hypertensive emergency prior to being prescribed 
antihypertensive therapy and 1 to 2% will progress while treated with anti-hypertensive therapy during their lifetime [2,4]. The mortality rate, if hypertensive emergency remains untreated, at 1 
and 5 years is 70 to 90% and 100% respectively.
CASE PRESENTATION
A 44 year old white male with a medical history positive for hypertension presents to the emergency room with a chief 
complaint of headache that started about three days ago, somewhat 
lessened by aspirin.  The onset is during light activity and has been intermittent; it is still present upon admission.  The patient has a 
history of noncompliance, prescribed metoprolol tartrate 50mg twice daily, and in checking with his pharmacy it is found that he has 
not had his medication filled in over a month.  The patient reports a weight gain of 20 pounds over the past few years and complains 
of excessive fatigue.  Review of systems is unremarkable with the 
exception of complaints of headache.  Physical exam reveals a blood pressure of 200/120 mmHg in the right arm, 198/122 mmHg in the 
left arm, and funduscopic exam reveals arteriovenous (A/V) nicking 
and papilledema.  Laboratory values are within normal limits except 
for BUN 32 mg/dL and SrCr 2.4 g/dL.
Keywords
•	Hypertensive crisis
•	Hypertensive emergency
•	Hypertension
•	Noncompliance
Abstract
Hypertensive crisis is defined as severe hypertension with a blood pressure of 
greater than 180/120 mmHg, and may be further classified as urgency or emergency. 
Hypertensive urgency occurs over days to weeks, whereas hypertensive emergency 
occurs in hours to days and the patient presents with evidence of end organ damage. 
Patients of any age may present with hypertensive crisis, common etiologies include 
undiagnosed hypertension, noncompliance with therapy or inadequate therapy.  Timely 
assessment of the patient is important and should include appropriate measurement 
of blood pressure, a thorough history and physical, and laboratory testing to evaluate 
for end organ damage.  Antihypertensive agents utilized in the setting of hypertensive 
emergency should be short acting and easy titratable, with examples including 
labetalol, esmolol, nitroprusside, nitroglycerin, fenoldopam, and nicardipine.  The 
patient may be switched to oral therapy once there is stable blood pressure control 
and there are no longer signs or symptoms of end organ damage.  Selection of oral 
therapy and goal blood pressure is dependent upon patient characteristics such as 
age, race and co-morbidities.
System Finding
Vital signs
Cardiovascular
Pulmonary
Renal
Neurologic
Ophthalmologic
Extremities
Irregular pulse, blood pressure differential and/or asymmetrical pulses (aortic 
dissection) 
S3 heart sound (heart failure), acute chest pain (myocardial infarction or aortic 
dissection) 
Jugular venous distension (heart failure), carotid pulsesDypsnea, pulmonary edema (crackles, 
rhonchi, rales)Oliguria or anuria, elevated serum creatinine 
and blood urea nitrogenSevere headache, dizziness, altered level of consciousness, lateral gazeRetinopathy, retinal hemorrhage, papilledema, visual changesEdema, diminished or delayed pulses
Table 1: Potential findings of end-organ compromise 2,3.
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DISCUSSIONPatients at any age may present with hypertensive emergency, common etiologies include undiagnosed hypertension, 
noncompliance with therapy or inadequate therapy [5].Clinically, 
the patient would exhibit a blood pressure greater than 180/120 mmHg and target organ dysfunction.  The patient in the case presents 
with a blood pressure of 200/120 mmHg and signs of end organ damage due to an elevated serum creatinine and an funduscopic 
exam revealing A/V nicking and papilledema.Timely assessment of a patient with hypertensive crisis is 
important and should include appropriate measurement of blood 
pressure, a thorough history and physical and specific testing for end 
organ damage.  The blood pressure should be checked in both arms utilizing an appropriate size cuff so as to not cause false elevations 
[6]. The cuff bladder must cover 80% of the arm circumference with the patient seated and the arm supported at heart level.The history and physical examination are crucial to provide details regarding end organ damage.  Patients with a history of 
hypertension should be assessed for duration of the disease, baseline 
blood pressure values and severity [2,5,7].  Additionally, a thorough 
medication history should be performed, including both over-the-counter and prescription medications, to evaluate for therapies that may precipitate a hypertensive crisis.      
ANTI-HYPERTENSIVE AGENTS
The goal in hypertensive emergency is a reduction in MAP by 
no more than 25% within the first hour, then reduce to 160/110 to 100 mmHg within the next 2 to 6 hours [8].There are several classes 
of medications available for treatment of hypertensive emergency; 
choice of therapy should be based upon end organ damage as 
outlined in (Table 2) [2,3].  Patients with hypertensive emergency 
will be admitted to the hospital and treated with intravenous therapy 
as it is considered to be life-threatening.  Preferred agents should 
be short acting and easily titratable; examples include esmolol, 
labetalol, nicardipine, fenoldopam, nitroglycerin and nitroprusside.
Esmolol and labetalol are both beta-adrenergic blocking agents 
utilized in the treatment of hypertensive emergency [2,3,7].  The 
antihypertensive effects of labetalol administered intravenously 
begin within 2 to 5 minutes, and peak at 5 to 15 minutes.  Labetalol 
lowers blood pressure by reducing peripheral vascular resistance while maintaining cardiac output in contrast to esmolol which 
lowers blood pressure by reducing cardiac output.  Esmolol has an onset of action within 60 seconds and duration of 10 to 20 minutes. 
It should be used with caution in patients with chronic obstructive 
lung disease and avoided in patients already on beta-blocker 
therapy; patients with bradycardia and those with decompensate heart failure [9].Nicardipine is a second generation derivative calcium channel 
blocker with a high vascular selectivity.  It has an onset of action 
between 5 to 15 minutes with duration of 4 to 6 hours and possesses 
coronary and cerebral vasodilatory properties [10].  Fenoldopam 
is a selective dopamine-1-receptor antagonist that reduces blood 
pressure by its vasodilatory action of peripheral dopamine-1 receptors resulting in systemic and renal vasodilation.  The onset 
of action is within 5 minutes with a duration between 30 to 60 
minutes [7,11].  Fenoldopam has efficacy in the setting of impaired renal function as clinical evidence has shown an improvement in 
creatinine clearance, renal blood flow and sodium excretion in 
hypertensive patients [12]. Its use should be avoided in patients with increased intraocular pressure and intracranial hypertension.Sodium nitroprusside and nitroglycerin are effective in the 
treatment of hypertensive emergency in specific scenarios.  Sodium 
nitroprusside is both an arterial and venous vasodilator with an 
immediate onset and short duration of action.  It should be used with 
caution in patients with renal or liver dysfunction, cerebrovascular accident and coronary artery disease.  Sodium nitroprusside 
contains 44% cyanide by weight that is released non-enzymatically 
and metabolized in the liver to thiocyanate which is eliminated 
renally [2,3,7]. Removal of the cyanide from the system is dependent 
upon the availability of thiosulfate, required for metabolism from 
cyanide to thiocyanate, renal function and liver function.  Cyanide accumulation may result in coma, encephalopathy, convulsions, 
respiratory failure and irreversible neurological irregularities. 
Thiocyanate toxicity manifests as psychosis, delirium and possible 
hypothyroidism.  Sodium nitroprusside should be reserved for 
patients not responding to other IV antihypertensive agents due to the potential toxicity.  Nitroglycerin is a preload and after load, 
at higher doses, reducing agent with efficacy in patients with acute coronary syndrome or acute pulmonary edema presenting with hypertensive emergency. 
Medication Population Dosing
Labetalol
Post-operative hypertension, Ischemic stroke, Hypertensive 
encephalopathy, Acute cardiac ischemia, Eclampsia
20 to 40mg IV q 30 min (max 300 mg/day)
2 mg/min continuous infusion (max 300 mg/
day)Esmolol Post-operative hypertension 500 mcg/kg load over 1 minute, infuse at 25 to 50 mcg/kg/min, titrate by 25 mcg/kg/min q 
10 to 20 min (max 300 mcg/kg/min)Nicardipine Post-operative hypertension, Ischemic stroke, Hypertensive encephalopathy, Acute renal failure, Eclampsia, Systolic heart failure 5 mg/hr, increase by 2.5 mg/hr q 5 to 15 min (max 15 mg/hr)
Fenoldopam
Ischemic stroke, Hypertensive encephalopathy, Acute renal failure, Systolic heart failure 0.1 to 0.3 mcg/kg/min, titrate by 0.1 mcg/kg/min q 15 min (max 1.6 mcg/kg/min)Sodium Nitroprusside Systolic heart failure 0.5 mcg/kg/min, titrate by 0.5 mcg/kg/min 
(max 2 mcg/kg/min)Nitroglycerin Acute cardiac ischemia with esmolol or labetalol 5 mcg/min, titrate by 5 mcg/min q 5 to 10 min 
(max 60 mcg/min) 
Table 2:  Targeted therapies2,3,7.
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MONITORING
Once therapy is initiated blood pressure should be measured 
every 15 to 30 minutes to evaluate response to therapy [13]. 
Ongoing physical assessment, laboratory and diagnostic testing 
should be performed during treatment to identify resolution of and 
new-onset end organ damage.  The patient may be switched to oral 
therapy once the blood pressure is stable and there are no longer signs or symptoms of end organ damage.  Selection of oral therapy 
and goal blood pressure is dependent upon patient characteristics 
such as age, race and co-morbidities [14].
OUTPATIENT THERAPY
Current guideline recommendations are to initiate therapy 
with a thiazide diuretic, dihydropyridine calcium channel blocker, 
angiotensin converting enzyme inhibitor (ACE inhibitor) or 
angiotensin receptor blocker (ARB) and titrate to a goal diastolic 
blood pressure of less than 90 mmHg [14]. The preferred agent in 
patients with diabetes mellitus and/or chronic kidney disease is 
either an ACE inhibitor or ARB, and in African American patients 
dihydropyridine calcium channel blocker or thiazide diuretic. Otherwise, selection of agent is dependent upon medication allergies, 
regimen, availability and cost.  Patients should be monitored for 
attainment of blood pressure goal monthly, if not at goal current 
therapy dose should be increased or another antihypertensive agent from a different class added to therapy.  Blood pressure should 
continue to be assessed until the patient reaches goal blood pressure. 
If the patient is unable to reach goal on a two drug therapy regimen at maximum therapeutic dose, a third antihypertensive medication 
should be added to the regimen.  Current recommendations are to 
not prescribe the use of ACE inhibitors and ARBs simultaneously; 
other medication classes of antihypertensive medication may be 
prescribed to gain control of blood pressure if the patient requires greater than a three drug regimen [14]. These include potassium sparing diuretics, vasodilators and alpha agonists.
The goal blood pressure is dependent upon age.  Patients less 
than 60 years of age should be titrated on medication to a goal blood pressure of less than 140/90 mmHg, if greater than or equal to 60 
years of age the goal blood pressure is less than 150/90 mmHg 
[14]. Patients presenting with a blood pressure of greater than 
160/100 mmHg should be initiated on therapy with two different antihypertensive therapies.
CASE CONCLUSION
The goal of the patient’s therapy would be a reduction in MAP 
by no more than 25% within the first hour, then reduce to 160/100-110 mmHg within the next 2 to 6 hours using nicardipine 5mg/
hr titrate by 2.5 mg/hr every 5 to 15 minutes to a maximum of 15 
mg/hr, at goal reduce to 3 mg/hr.  An alternative agent would be 
fenoldopam 0.1 to 0.3 mcg/kg/min titrate by 0.1 mcg/kg/min to a 
maximum of 1.6 mcg/kg/min.  The patient present with A/V nicking and papilledema was indicating increased ocular pressure which is 
a contraindication to the use of fenoldopam.  Nicardipine would be the preferred agent in this patient due to the presence of acute renal failure.
The goal blood pressure and oral antihypertensive therapy 
for this patient are based upon his age, race and past medical 
history [14]. The patient presented with an initial blood pressure 
of 200/120 mmHg in the right arm, 198/122 mmHg in the left 
arm and signs of acute kidney injury, but this is reversible with appropriate management of the hypertensive crisis.  The patient 
was taking metoprolol tartrate at home, but current evidence no 
longer supports beta-blocker therapy as a first-line in the treatment 
of hypertension [14].  Appropriate therapy for this patient would be initiation of amlodipine 5 mg daily with chlorthalidone 25 mg daily. 
Acutely the patient was treated with the dihydropyridine calcium 
channel blocker nicardipine, once the blood pressure is controlled and there are no longer signs of end organ failure nicardipine may 
be titrated off upon initiation of amlodipine.  Initiation of dual 
therapy is appropriate based upon the patient presenting with a 
blood pressure of greater than 160/100 mmHg to reach his goal of less than 140/90 mmHg [14].
Prior to discharge the patient should receive verbal and written counseling on amlodipine and chlorthalidone.  Recommendations 
on purchase of home blood pressure monitoring devices should 
be provided, along with instructions on how to appropriately monitor at home [15] .These instructions should include selection of appropriate arm cuff size, when to monitor, how often to monitor, 
and what to do in situations of multiple elevated blood pressures. 
The patient should be told to take multiple readings (up to 3 at one 
minute intervals), monitor at the same time each day, and record and 
bring measurement log to follow-up appointments [15]. He should 
also receive counseling on noncompliance and the co-morbidities 
associated with non- and under- treatment of hypertension.  A study 
by Saguner et al found that non adherence was the most important factor associated with hypertensive crisis [16].  The study concluded that improvement of medical adherence in antihypertensive therapy would assist in preventing admissions for hypertensive crisis.
The pharmacist’s role initially begins with medication counseling in the inpatient setting.  
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